- Xebra Brands (CSE:XBRA) has received approval from the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) for its second CBD product authorization in Mexico
- The company has also obtained authorization for importing, launching and selling an additional 250 mg tincture
- Its second product approval by COFEPRIS, reaffirms Xebra Brands reaffirms as a leader in the Mexican CBD industry
- Shares of Xebra Brands are up 5 per cent to C$0.105 as of 10:38 am ET
Xebra Brands (CSE:XBRA) has received approval from the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) for its second CBD product authorization in Mexico.
In a news release, the Vancouver-based company stated it has also obtained authorization for importing, launching and selling an additional 250 mg tincture.
“We are thrilled to receive approval from COFEPRIS for an additional CBD product to be sold in Mexico,” Rodrigo Gallardo, interim CEO of Xebra Brands, said in a statement. “This demonstrates not only the responsiveness of regulatory authorities but also the trust they place in our commitment to providing safe, legal and effective CBD products to consumers over what is currently available. We are excited to continue our mission of expanding access to premium CBD products in Mexico.”
Xebra Brands’ 250mg tincture is formulated with the same formula as its previous offerings. Now that the company has received its second product approval by COFEPRIS, Xebra Brands reaffirms its position as a leader in Mexico’s CBD industry.
Xebra Brands is focused on processing, manufacturing, designing, and delivering cannabis products in areas ranging from wellness to leisure. Its focuses include beverages, wellness and leisure.
Shares of Xebra Brands (CSE:XBRA) are up 5 per cent to C$0.105 as of 10:38 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the Xebra Brands Ltd. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.